ARTICLE | Finance
Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT
By Paul Bonanos, Director of Biopharma Intelligence
May 9, 2024 10:24 PM UTC
In a busy week for venture fundings, Bluejay, Attovia and Zenas all drew nine-figure rounds to advance programs in the clinic, while Flagship introduced a new start-up to explore the viral proteome.
Frazier Life Sciences and an undisclosed firm co-led the $182 million series C announced Thursday by Bluejay Therapeutics Inc., with crossover investors joining the round. Bluejay is conducting a Phase I/II trial of HBsAg-targeting antibody BJT-778 to treat chronic hepatitis D viral infection…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652374/venture-report-big-rounds-for-bluejay-attovia-and-zenas